Today provided financial results for the first quarter 2025, ending March 31, 2025, and provided a business update.
1 month ago

Cellectis (NASDAQ:CLLS) Stock Passes Above 50-Day Moving Average - Time to Sell?
4 days ago

Despite these insights, Cellectis said UCART123 is being deprioritized so the company's resources can be focused on its two other CAR-Ts. These...
8 months ago

Cellectis said late Wednesday that it plans to offer up to $200 million in securities, comprising ordinary shares, American depositary...
1 week ago

The biotechnology sector has long been a battlefield of high risks and high rewards, where companies like Cellectis (NASDAQ: CLLS) balance...
1 week ago

Summary · Cellectis SA's pipeline consists of allogeneic CAR T-cell therapies that have the potential to make meaningful dents in heme...
1 month ago

Idorsia Pharmaceuticals CEO André Muller brings extensive biotech leadership experience to Cellectis board. Two directors step down as...
2 weeks ago

Cellectis S.A. (NASDAQ:CLLS) may offer up to $200M in securities over time. Securities may include ordinary shares, American depositary shares,...
1 week ago

Cellectis SA ( ($CLLS) ) has provided an update. On June 26, 2025, Cellectis held a shareholders' meeting where approximately 57% of voting...
2 weeks ago

Discover how Cellectis SA (CLLS) is advancing its CAR T therapies and securing financial stability through strategic partnerships and...
2 months ago